La Roche-Posay Effaclar Salicylic Acid Acne Treatment to Minimize Pores, Clear Acne Blemishes and Post Acne Marks - Image 1
La Roche-Posay Effaclar Salicylic Acid Acne Treatment to Minimize Pores, Clear Acne Blemishes and Post Acne Marks - Image 2
La Roche-Posay Effaclar Salicylic Acid Acne Treatment to Minimize Pores, Clear Acne Blemishes and Post Acne Marks - Image 3
La Roche-Posay Effaclar Salicylic Acid Acne Treatment to Minimize Pores, Clear Acne Blemishes and Post Acne Marks - Image 4

La Roche-Posay Effaclar Salicylic Acid Acne Treatment to Minimize Pores, Clear Acne Blemishes and Post Acne Marks

La Roche-Posay Anthelios AOX Daily Antioxidant Serum with SPF, Face Moisturizer with Sunscreen and Vitamin C & E, Oil Free Face Sunscreen for Sensitive Skin, Moisturizing Sun Protection
La Roche-Posay Effaclar Mat | Daily Moisturizer For Oily Skin | Visibly Reduces The Look Of Pores | Oil-Free Mattifying Moisturizer | Smooths Skin Texture | Non-Comedogenic & Dermatologist Tested
0 out of 5
( There are no reviews yet. )

$42.99

Skin Type Oily, Acne Prone, Combination
Product Benefits User saw a 45% reduction of pimples in 4 weeks and 21% reduction of whiteheads and blackheads in 4 weeks
Use for Face
Scent Scented
Special Ingredients 1.5% salicylic acid, glycolic acid, and lipo-hydroxy acid
Category:
  Ask a Question
Add to wishlist
Compare

Description

New Effaclar Salicylic Acid Acne Serum clears acne blemishes and prevents new breakouts, while also visibly reducing pores, fine lines, and post-acne marks.

Benefits

User saw a 45% reduction of pimples in 4 weeks and 21% reduction of whiteheads and blackheads in 4 weeks

Suggested Use

Start with one application daily, then gradually increase to two or three times daily if needed

Additional information

Weight 3.17 kg
Dimensions 1.39 × 2.17 × 4.29 cm

Reviews

There are no reviews yet.

Be the first to review “La Roche-Posay Effaclar Salicylic Acid Acne Treatment to Minimize Pores, Clear Acne Blemishes and Post Acne Marks”

General Inquiries

There are no inquiries yet.